Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 6/20 | 0.70 |
| ▸ | ULK1 | O75385 | 3/20 | 0.62 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.60 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 4/20 | 0.58 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27654586 | 0.91 | NTRK1 (0.64) | NTRK1ULK1NTRK3NTRK2IGF1R | |
| SCHEMBL4074989 | 0.91 | NTRK1 (0.64) | NTRK1ULK1NTRK3NTRK2IGF1R | |
| SCHEMBL4551106 | 0.90 | NTRK1 (0.65) | NTRK1ULK1NTRK3NTRK2IGF1R | |
| SCHEMBL4160193 | 0.90 | NTRK1 (0.65) | NTRK1ULK1NTRK3NTRK2IGF1R | |
| SCHEMBL4075190 | 0.90 | NTRK1 (0.65) | NTRK1IGF1RPAK4PAK1SRC | |
| SCHEMBL4155683 | 0.90 | NTRK1 (0.65) | NTRK1IGF1RPAK4PAK1SRC | |
| SCHEMBL4155715 | 0.88 | NTRK1 (0.68) | NTRK1ULK1NTRK3NTRK2IGF1R | |
| SCHEMBL4074253 | 0.88 | NTRK1 (0.73) | NTRK1ULK1IGF1RPAK4 | |
| SCHEMBL4076569 | 0.86 | NTRK1 (0.65) | NTRK1ULK1IGF1RPAK4GSK3B | |
| SCHEMBL4066282 | 0.86 | IGF1R (0.71) | NTRK1ULK1IGF1RPAK4PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1877057-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006115452-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885ULK1 3406/4885NTRK3 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.